Literature DB >> 17073624

Engineered T cell receptors and their potential in molecular medicine.

John J Miles1, Sharon L Silins, Scott R Burrows.   

Abstract

T cell receptors are among the most specific biological structures found in nature and are therefore excellent candidates for the molecular targeting of antigen. It is becoming increasingly apparent that common sets of T cell receptors are frequently used in humans to combat pathogen and cancer derived threats. Given that many of these conserved T cell receptors have high affinity for their target ligands, there is potential to amass virtual banks of "off-the-shelf" receptors for use in a wide range of immunotherapeutic strategies. Additionally, such T cell receptors could become basic blueprints for artificial enhancement through mutagenesis, thereby creating an even better 3-dimensional fit for their cognate targets. Indeed, preliminary approaches using both "natural" and "supernatural" T cell receptors have shown promise in treating autoimmunity and malignancy. This review will discuss these studies and other approaches through which T cell receptors can be exploited in immunodiagnostics, pathogen control and gene therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073624     DOI: 10.2174/092986706778521959

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  11 in total

1.  Germ line-governed recognition of a cancer epitope by an immunodominant human T-cell receptor.

Authors:  David K Cole; Fang Yuan; Pierre J Rizkallah; John J Miles; Emma Gostick; David A Price; George F Gao; Bent K Jakobsen; Andrew K Sewell
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

2.  Combinations of affinity-enhancing mutations in a T cell receptor reveal highly nonadditive effects within and between complementarity determining regions and chains.

Authors:  Brian G Pierce; Jaafar N Haidar; Yong Yu; Zhiping Weng
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

Review 3.  Stem cell-based anti-HIV gene therapy.

Authors:  Scott G Kitchen; Saki Shimizu; Dong Sung An
Journal:  Virology       Date:  2011-01-17       Impact factor: 3.616

Review 4.  Stem cell-based approaches to treating HIV infection.

Authors:  Scott G Kitchen; Jerome A Zack
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

5.  Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice.

Authors:  Scott G Kitchen; Michael Bennett; Zoran Galić; Joanne Kim; Qing Xu; Alan Young; Alexis Lieberman; Aviva Joseph; Harris Goldstein; Hwee Ng; Otto Yang; Jerome A Zack
Journal:  PLoS One       Date:  2009-12-07       Impact factor: 3.240

6.  Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression.

Authors:  Dimitrios N Vatakis; Balamurugan Arumugam; Sohn G Kim; Gregory Bristol; Otto Yang; Jerome A Zack
Journal:  Mol Ther       Date:  2013-03-12       Impact factor: 11.454

7.  Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope.

Authors:  Rebekah M Brennan; John J Miles; Sharon L Silins; Melissa J Bell; Jacqueline M Burrows; Scott R Burrows
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

9.  In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells.

Authors:  Scott G Kitchen; Bernard R Levin; Gregory Bristol; Valerie Rezek; Sohn Kim; Christian Aguilera-Sandoval; Arumugam Balamurugan; Otto O Yang; Jerome A Zack
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

Review 10.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.